Microcytometer enrichment and detection of colon cancer*

结肠癌的微细胞计数富集和检测*

• 批准号: 7021339
• 负责人: JOHN Charles GERDES
• 金额: $ 10万
• 依托单位: MICRONICS, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-03 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7021339
• 关键词: blood; clinical research; colon neoplasms; microfluidics; neoplasm /cancer; neoplastic cell

DESCRIPTION (provided by applicant): Circulating tumor cells in blood are detectable in late stage colon cancer patients. However, adequately sensitive and specific methods have not been identified for early diagnosis or detection of micrometastatic cells. Also, current approaches are cumbersome and therefore not suitable for use by clinical diagnostic laboratories. Routine clinical use will require a substantial improvement in rare tumor cell enrichment from blood, identification of an appropriate tumor marker that identifies the majority of early stage patients without false positives or negatives, and an integrated methodology more compatible with clinical laboratory testing. Our ultimate goal is to enable reproducible detection and confirmation of rare colon cancer cells from blood in an economical integrated clinical laboratory test or point-of-care platform. During phase I we will confirm the feasibility of our approach using whole blood spiked with colon cancer cells. We propose a credit-card sized microfluidic cell sorting device for sorting and detecting tumor cells in blood that will be much faster and have high specificity and several orders of magnitude greater sensitivity than current flow cytometry. Individual steps will be performed using on-card fluidic movement and valving logic, with final performance enabled through the design of an integrated microfluidic circuit that automates the process. The completion of our phase I specific aims will result in a bread board platform that will be tested using clinical specimens from colon cancer patients in collaboration with Fred Hutchinson Cancer Research Center. Colorectal cancer affects approximately 147,000 people in the United States each year and is most effectively treated when diagnosed at an early stage. Consequently, colon cancer screening is an effective means for decreasing mortality secondary to colon cancer. Current colon cancer screening methods include either sigmoidoscopy or colonoscopy. However, only 25-35 percent of adults undergo screening because of fear of discomfort from the bowel preparation and, in the case of colonoscopy, the cost of the screening test. The colon cancer screening test we will develop uses a blood specimen for diagnosis to overcome the drawbacks of current screening methods. The approach leverages recent advances in molecular assays together with Micronics' microfluidics and cell sorting technologies to develop an assay that can be utilized in routine clinical or point of care settings. This will result in better screening compliance and save lives through earlier detection.

描述(由申请人提供)： 晚期结肠癌患者血液中可检测到循环中的肿瘤细胞。然而，对于微转移细胞的早期诊断或检测，还没有找到足够灵敏和特异的方法。此外，目前的方法很繁琐，因此不适合临床诊断实验室使用。常规的临床应用将需要从血液中浓缩罕见的肿瘤细胞，识别出一种适当的肿瘤标志物，以识别大多数没有假阳性或假阴性的早期患者，以及一种与临床实验室测试更兼容的综合方法学。我们的最终目标是能够在经济的综合临床实验室测试或护理点平台中对血液中罕见的结肠癌细胞进行可重复的检测和确认。在第一阶段，我们将确认我们的方法的可行性，使用掺入结肠癌细胞的全血。我们提出了一种信用卡大小的微流控细胞分选装置，用于分选和检测血液中的肿瘤细胞，它将比目前的流式细胞仪更快、更具特异性和几个数量级的灵敏度。各个步骤将使用卡上流体运动和阀门逻辑来执行，最终性能通过设计一个集成的微流体电路来实现，该电路使该过程自动化。我们第一阶段特定目标的完成将产生一个面包板平台，该平台将与弗雷德·哈钦森癌症研究中心合作，使用结肠癌患者的临床标本进行测试。在美国，结直肠癌每年影响大约147,000人，在早期被诊断出来时是最有效的治疗方法。因此，结肠癌筛查是降低继发于结肠癌的死亡率的有效手段。目前的结肠癌筛查方法包括乙状结肠镜检查或结肠镜检查。然而，只有25%-35%的成年人接受筛查，因为担心肠道准备带来的不适，就结肠镜检查而言，筛查测试的费用。我们将开发的结肠癌筛查测试使用血液样本进行诊断，以克服目前筛查方法的缺点。该方法利用分子分析方面的最新进展以及微电子公司的微流体和细胞分选技术来开发一种可用于常规临床或护理场所的分析方法。这将导致更好的筛查遵从性，并通过更早的检测拯救生命。